Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03885661 · ClinicalTrials.gov registry record · Phase 1
Vascepa to Accelerate Lipoprotein Uptake and Elimination
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03885661: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT03885661 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03885661, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is a Phase 1 pilot/feasibility mechanistic experiment to help clarify the mechanism of action of an EPA-rich fish oil preparation, icosapent ethyl, on lipid changes in statin-treated patients with residual triglyceridemia.
Interventions
- DRUG Icosapent Ethyl 1000 MG [Vascepa]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-01-11 |
| Est. Completion | 2021-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03885661
The ClinicalTrials.gov registry entry for NCT03885661 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Icosapent Ethyl 1000 MG [Vascepa] is the first listed.
NCT03885661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03885661 about?
NCT03885661 is a clinical study titled "Vascepa to Accelerate Lipoprotein Uptake and Elimination". This study is a Phase 1 pilot/feasibility mechanistic experiment to help clarify the mechanism of action of an EPA-rich fish oil preparation, icosapent ethyl, on lipid changes in statin-treated patients with residual triglyceridemia.
What is the current status of trial NCT03885661?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-01-11. Estimated completion is 2021-06.
What interventions are being tested in trial NCT03885661?
The interventions under investigation include: Icosapent Ethyl 1000 MG [Vascepa] (DRUG).
Who is sponsoring clinical trial NCT03885661?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.